COVIGILENT APP FOR COVID 19 COUGH

Ms. V. Vidhya

Assistant Professor

Department of MBA, SIMS

Cancer care specialist HCG and technology specialist WIPRO had jointly developed an AI powered app called AIO cough analysis tool for COVID 19 which is launched for free globally. This AI app will be able to detect the early stage of COVID 19 and can be used on large scale screening of patients who are associated with cough as their primary symptoms.

As per HCG this app differentiate COVID 19 cough with that of the seasonal cough or bronchitis. It acquires cough signals by ‘do it yourself’ and it is analyzed by the experts without any interventions from healthcare professionals. It captures audio and demographic data’s and upload to the cloud server for analysis using AI technology. The signals are analyzed with an algorithm to identify the cough of the people who were infected with the virus. The app does not requires large investment or instruments. An android phone used by the patient serves as the recording device and risk factors are given to the user in few seconds

Covigilent app is developed by Wipro technologies in association with HCG cancer specialist supported by Government of Karnataka, Bhakthi Vedanta Hospital, Mumbai and BMRCI.

We have already anticipated the second wave of the infections this app will help us to identify the vulnerable category with high risk contacts who can be effectively isolated before they are diagnosed as COVID 19 positive patients. The mission of this app is to help the doctors and healthcare professionals to speed up the decision making in emergencies and to reduce the constraints. HCG is already in the forefront in fighting COVID 19 by starting plasma therapy and other clinical trials and this app is another initiative during this pandemic.

The app is user friendly and is made freely available to the common man as a screening tool for COVID 19 using AI algorithms and machine learning. Covigilent app is tailor made, cost effective and easily reproducible. It can screen large number of patients with greater accuracy which indirectly reduces the burden on confirmatory testing.

Majority of the COVID cases are either in early stage or asymptomatic. This can be interpreted in two ways the positive side being less health care burden and mortality.